Berry Genomics Co Ltd
SZSE:000710
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
|
Berry Genomics Co Ltd
SZSE:000710
|
4.4B CNY |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
407.7B USD |
Loading...
|
|
| US |
|
Astria Therapeutics Inc
NASDAQ:ATXS
|
326.4B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
208.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
185.3B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
125.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.5B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
71.1B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
39.9B EUR |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Berry Genomics Co Ltd
Glance View
Berry Genomics Co., Ltd. engages in the gene detection and sales of equipment and reagents of high-throughput sequencing technology. The company is headquartered in Beijing, Beijing and currently employs 1,490 full-time employees. The firm's business is comprised of basic scientific research services, medical testing services, testing reagent sales and testing equipment sales. The basic scientific research services business provides the clients with multiple sequencing platforms for testing projects, such as transcriptome sequencing, human whole exome sequencing and whole genome sequencing. The medical testing services business include tumor genetic testing services, genetic disease genetic testing services and reproductive health testing services. The firm sells a range of reagents and equipment, including NextSeq CN500 gene sequencer and general reagents for sequencing reactions.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Berry Genomics Co Ltd is -27.1%, which is below its 3-year median of -26.6%.
Over the last 3 years, Berry Genomics Co Ltd’s Net Margin has decreased from -11.4% to -27.1%. During this period, it reached a low of -37.1% on Dec 31, 2023 and a high of -11.4% on Sep 30, 2022.
